PL173023B1 - Sposób wytwarzania pochodnych imidazolu - Google Patents

Sposób wytwarzania pochodnych imidazolu

Info

Publication number
PL173023B1
PL173023B1 PL93297955A PL29795593A PL173023B1 PL 173023 B1 PL173023 B1 PL 173023B1 PL 93297955 A PL93297955 A PL 93297955A PL 29795593 A PL29795593 A PL 29795593A PL 173023 B1 PL173023 B1 PL 173023B1
Authority
PL
Poland
Prior art keywords
formula
alkyl
compound
hydrogen
compounds
Prior art date
Application number
PL93297955A
Other languages
English (en)
Polish (pl)
Other versions
PL297955A1 (en
Inventor
Holger Heitsch
Rainer Henning
Adalbert Wagner
Hermann Gerhards
Reinhard Becker
Bernward Schölkens
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of PL297955A1 publication Critical patent/PL297955A1/xx
Publication of PL173023B1 publication Critical patent/PL173023B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
PL93297955A 1992-03-07 1993-03-05 Sposób wytwarzania pochodnych imidazolu PL173023B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4207241 1992-03-07

Publications (2)

Publication Number Publication Date
PL297955A1 PL297955A1 (en) 1993-09-20
PL173023B1 true PL173023B1 (pl) 1998-01-30

Family

ID=6453463

Family Applications (1)

Application Number Title Priority Date Filing Date
PL93297955A PL173023B1 (pl) 1992-03-07 1993-03-05 Sposób wytwarzania pochodnych imidazolu

Country Status (25)

Country Link
US (1) US5604251A (US20070244113A1-20071018-C00087.png)
EP (1) EP0560177B1 (US20070244113A1-20071018-C00087.png)
JP (1) JP3542813B2 (US20070244113A1-20071018-C00087.png)
KR (1) KR930019637A (US20070244113A1-20071018-C00087.png)
CN (1) CN1036341C (US20070244113A1-20071018-C00087.png)
AT (1) ATE230732T1 (US20070244113A1-20071018-C00087.png)
AU (1) AU663565B2 (US20070244113A1-20071018-C00087.png)
BR (1) BR9300761A (US20070244113A1-20071018-C00087.png)
CA (1) CA2091135A1 (US20070244113A1-20071018-C00087.png)
CZ (1) CZ281983B6 (US20070244113A1-20071018-C00087.png)
DE (1) DE59310323D1 (US20070244113A1-20071018-C00087.png)
DK (1) DK0560177T3 (US20070244113A1-20071018-C00087.png)
ES (1) ES2187501T3 (US20070244113A1-20071018-C00087.png)
FI (1) FI930970A (US20070244113A1-20071018-C00087.png)
HU (1) HUT64041A (US20070244113A1-20071018-C00087.png)
IL (1) IL104971A0 (US20070244113A1-20071018-C00087.png)
MA (1) MA22814A1 (US20070244113A1-20071018-C00087.png)
NO (1) NO303632B1 (US20070244113A1-20071018-C00087.png)
NZ (1) NZ247059A (US20070244113A1-20071018-C00087.png)
PH (1) PH31466A (US20070244113A1-20071018-C00087.png)
PL (1) PL173023B1 (US20070244113A1-20071018-C00087.png)
RU (1) RU2116300C1 (US20070244113A1-20071018-C00087.png)
SK (1) SK279109B6 (US20070244113A1-20071018-C00087.png)
TW (1) TW215434B (US20070244113A1-20071018-C00087.png)
ZA (1) ZA931585B (US20070244113A1-20071018-C00087.png)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
CZ283315B6 (cs) * 1992-12-17 1998-02-18 Sankyo Company Limited Bifenylové deriváty, způsob výroby a farmaceutické prostředky k léčení hypertense a srdečních onemocnění, které tyto deriváty obsahují
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
HUP0002351A3 (en) 1996-02-20 2001-10-29 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides, intermediates and process for preparing them
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
EP0944312B9 (en) * 1996-12-13 2006-07-05 ZymoGenetics, Inc. Compositions and methods for stimulating bone growth
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
JP2001520170A (ja) 1997-10-16 2001-10-30 ボード・オヴ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム Nf−at3機能に関連した心肥大動物モデルと治療法
DE19802969A1 (de) 1998-01-27 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von S-Alkyl(Aryl)-substituierten Imidazol-Derivaten
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
HUP0201320A2 (en) 1999-03-19 2002-08-28 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US20040082613A1 (en) * 2002-06-28 2004-04-29 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
WO2004112763A2 (en) * 2003-05-21 2004-12-29 Board Of Regents, The University Of Texas System Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure
AU2004253967B2 (en) * 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004285961A1 (en) * 2003-11-03 2005-05-12 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
JP2007510728A (ja) * 2003-11-03 2007-04-26 ミオゲン インコーポレイティッド 心血管疾患を治療するための1,4−ジヒドロピリジン化合物、薬学的組成物、および方法
WO2005058280A2 (en) * 2003-12-12 2005-06-30 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
CA2560528A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
EP1737447A1 (en) * 2004-03-22 2007-01-03 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
WO2006007213A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US20090220507A1 (en) * 2005-07-22 2009-09-03 Sucharov Carmen C Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
CA2634437A1 (en) * 2005-12-20 2007-07-05 Gilead Colorado, Inc. 4,7-dihydrothieno¬2,3-b|pyridine compounds and pharmaceutical compositions
PL2056882T3 (pl) 2006-08-01 2013-03-29 Univ Texas Identyfikacja mikro-RNA, który aktywuje ekspresję łańcucha ciężkiego beta-miozyny
JP5587777B2 (ja) 2007-07-31 2014-09-10 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 線維症をモジュレートするマイクロrnaファミリー及びその使用
CN102036689B (zh) 2008-03-17 2014-08-06 得克萨斯系统大学董事会 神经肌肉突触维持和再生中涉及的微小rna的鉴定
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5135197A (en) * 1990-08-30 1992-08-04 Qualtec Data Products, Inc. Equipment security method and apparatus
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
CA2115989A1 (en) * 1991-08-19 1993-03-04 George Albert Boswell Angiotensin ii receptor blocking imidazolinone derivatives
DE4221009A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Cyclohexanderivate
CZ283315B6 (cs) * 1992-12-17 1998-02-18 Sankyo Company Limited Bifenylové deriváty, způsob výroby a farmaceutické prostředky k léčení hypertense a srdečních onemocnění, které tyto deriváty obsahují

Also Published As

Publication number Publication date
DK0560177T3 (da) 2003-04-14
CA2091135A1 (en) 1993-09-08
CN1036341C (zh) 1997-11-05
AU3401193A (en) 1993-09-09
RU2116300C1 (ru) 1998-07-27
BR9300761A (pt) 1993-09-14
FI930970A0 (fi) 1993-03-04
AU663565B2 (en) 1995-10-12
JPH069572A (ja) 1994-01-18
NZ247059A (en) 1995-03-28
ZA931585B (en) 1993-09-27
JP3542813B2 (ja) 2004-07-14
TW215434B (US20070244113A1-20071018-C00087.png) 1993-11-01
PL297955A1 (en) 1993-09-20
EP0560177B1 (de) 2003-01-08
CZ381192A3 (en) 1993-12-15
EP0560177A1 (de) 1993-09-15
SK381192A3 (en) 1998-06-03
NO303632B1 (no) 1998-08-10
NO930817D0 (no) 1993-03-05
HUT64041A (en) 1993-11-29
IL104971A0 (en) 1993-07-08
CN1076192A (zh) 1993-09-15
CZ281983B6 (cs) 1997-04-16
US5604251A (en) 1997-02-18
DE59310323D1 (de) 2003-02-13
FI930970A (fi) 1993-09-08
MA22814A1 (fr) 1993-10-01
NO930817L (no) 1993-09-08
ATE230732T1 (de) 2003-01-15
SK279109B6 (sk) 1998-06-03
KR930019637A (ko) 1993-10-18
PH31466A (en) 1998-11-03
ES2187501T3 (es) 2003-06-16
HU9300618D0 (en) 1993-05-28

Similar Documents

Publication Publication Date Title
PL173023B1 (pl) Sposób wytwarzania pochodnych imidazolu
AU653760B2 (en) Azole derivatives, process for their preparation, and their use
SU727143A3 (ru) Способ получени производных 2-карбалкоксиаминобензимидазола или их солей
RU2047604C1 (ru) Замещенные азолы и способ их получения
ES2204888T3 (es) Isociclos y heterociclos imidazo-condensados como antagonistas de angiotensina ii.
RU2086542C1 (ru) Серосодержащие производные имидазола, способ их получения, новые промежуточные соединения и фармацевтическая композиция
US5183899A (en) Pyrazole derivative
SK15942001A3 (sk) 1-(p-Tienylbenzyl)imidazoly ako antagonisty receptorov angiotenzínu-(1-7), spôsob ich prípravy, ich použitie a farmaceutické prípravky, ktoré ich obsahujú
CZ282142B6 (cs) Cykloalkylsubstituované glutaramidové deriváty, farmaceutický prostředek obsahující tyto sloučeniny a použití
CS9100906A2 (en) Substituted azoles, method of their production, preparations that contain these compounds and their application
PT94568B (pt) Quinazolinonas substituidas como antagonistas da angiotensina ii
HUT64057A (en) Process for producing sulfonylbenzyl-substituted pyridone derivatives and pahrmaceutical compositions comprising same
JP3116256B2 (ja) (チオ)ウレア誘導体
US5714508A (en) Bicycle Derivatives of imidazole
KR100454890B1 (ko) 4,5-디아미노 피리미딘 유도체
HUT64341A (en) Methods for producing sulfonylbenzyl-substituted imidazo-pyridines and pharmaceutical preparatives containing them
LT3373B (en) Azole derivatives, process for preparing and using thereof